ExSure

Executive Summary

ExSure is a preclinical-stage Indian biotech startup leveraging a patented exosome-based platform to deliver anticancer drugs to both bulk tumor cells and cancer stem cells. By engineering exosomes (ExoDS) and utilizing proprietary isolation reagents (EXOSURE, LEUCOSURE, DENDROSURE), the company aims to reduce chemotherapy toxicity and improve relapse-free survival. Founded in 2020 and based in Mumbai, ExSure has raised approximately $400,000 and employs 10-50 staff. Its focus is on oncology, with services including stem-cell isolation, exosome characterization, and drug-delivery development. The company is currently in the preclinical stage, with no disclosed valuation or publicly available data from animal studies or IND filings. While the exosome platform is innovative and addresses a key unmet need in oncology, the early stage and limited funding present significant execution risks.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Data Readout for Lead Candidate ExoDS40% success
• Q4 2026Series A Funding Round50% success
• TBDResearch Partnership or Licensing Deal with Indian Pharma30% success